Randomized Controlled Trial Comparing Standard Treatment of Obstructive Sleep Apnea to Add-On Acetazolamide Treatment - NI

Anurag Ambikaprasad Tripathi0 个研究点目标入组 95 人开始时间: 待定最近更新: 2024年7月22日

试验速览

暂无简介。

•Patients of Obstructive Sleep Apnea with AHI of 5 and more with no active infections in 4 weeks prior to recruitment with Body Mass Index of at least 20 kg/m2 and Epsworth Sleepiness Score of at least 6.

•Refusal to participate
•Refusal of PAP therapy
•Allergy to sulfonamides
•Central sleep apnoea syndromes, dominant Cheyne-Stokes respiration, or significant sleep disorders including periodic limb movements or parasomnia
•Patients who had received OSA treatment within 4 weeks of the baseline visit
•Unstable pulmonary or gastrointestinal disease,
•Severe congestive heart failure, a history of life-threatening arrhythmias, severe cardiomyopathy
•Significant chronic kidney disease or hepatic disease
•Potassium levels less than 3 mmol/L
•Sodium levels less than 125 mEq/L
•History of mental illness or those on Amphetamines
•Drug or alcohol abuse, use of sedatives, severe cognitive impairment or
•Concurrent oncological diseases.
•Seizure disorders
•Prior to the treatment with AZM it will be confirmed that no obvious causes of upper airways obstruction have been detected in the nose, throat or lower jaw by examinations performed at the Department of Otorhinolaryngology.

发起方

Anurag Ambikaprasad Tripathi